Medtronic AneuRx Endovascular AAA Graft Should Be Approved - FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's AneuRx minimally invasive endovascular graft for abdominal aortic aneurysm repair was successfully implanted in 98% of the 416 patients treated in the company's pivotal trial to support premarket approval, study investigators said.
You may also be interested in...
Medtronic MIRACLE Foreshadows Resynchronized Approach To CHF Therapy
A clear clinical benefit demonstrated by Medtronic's InSync atrial synchronous biventricular pacing system in treating congestive heart failure could give FDA the impetus to bring resynchronization therapy to panel review as early as June.
Medtronic MIRACLE Foreshadows Resynchronized Approach To CHF Therapy
A clear clinical benefit demonstrated by Medtronic's InSync atrial synchronous biventricular pacing system in treating congestive heart failure could give FDA the impetus to bring resynchronization therapy to panel review as early as June.
Boston Scientific's Vanguard AAA Graft Effective For High-Risk Patients
Preliminary data from a study of Boston Scientific's Vanguard aortic endograft for treatment of abdominal aortic aneurysms (AAA) show a 97.6% success rate in high-risk patients. The results reinforce a growing consensus among clinicians that the minimally invasive procedure is preferable to standard open surgery for this population.